Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: Activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents

Journal of Medicinal Chemistry

Volumn 40, Issue 19, 1997, Pages 3040-3048

  Robson, Claire ^a   Meek, Michelle A ^b   Grunwaldt, Jan Dierk ^a,d   Lambert, Peter A ^b   Queener, Sherry F ^c   Schmidt, Dirk ^a,d   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 [4' [N [4'' (N' METHYLCARBAMOYL)BENZYL] N METHYLAMINO] 3' NITROPHENYL] 6 ETHYLPYRIMIDINE; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; FOLIC ACID ANTAGONISTS; INDICATORS AND REAGENTS; KINETICS; LIVER; LYMPHOMA, LARGE-CELL; MICE; PNEUMOCYSTIS; PYRIMIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA;

EID: 0030815212     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970055k     Document Type: Article

References (46)

1. Sirotnak, F. M., Burchall, J. J., Ensminger, W. B., Montgomery, J. A., Eds. Folate Antagonists as Therapeutic Agents; Academic Press: New York, 1984.
2. Berman, E. M.; Werbel, L. M. The renewed potential for folate antagonists in contemporary cancer chemotherapy. J. Med. Chem. 1991, 34, 479-485.
3. Schweitzer, B. I.; Dicker, A. P.; Bertino, J. R. Dihydrofolate reductase as a therapeutic target. FASEB J. 1990, 4, 2441-2452.
4. Fleming, G. F.; Schilsky, R. L. Antifolates: The next generation. Sem. Oncol. 1993, 11, 707-719.
5. Jolivet, J.; Cowan, K. H.; Clendenin, N. J.; Chabner, B. A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 1983, 309, 1094-1104.
6. Werbel, L. M. Design and synthesis of lipophilic antifolates as anticancer agents. In Folate Antagonists as Therapeutic Agents; Sirotnak, F. M., Burchall, J. J., Ensminger, W. B., Montgomery, J. A., Eds.; Academic Press: Orlando, FL, 1984; Vol. 1, pp 261-287.
7. Cavallito, J. C.; Nichol, C. A.; Brenckman, W. D.; DeAngelis, R. L.; Stickney, D. R.; Simmons, W. S.; Sigel, C. W. Lipid-soluble inhibitors of dihydrofolate reductase I. Kinetics, tissue distribution and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab. Disp. 1978, 6, 329-337
8. Hill, B. T.; Price, L. A. DDMP (2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine). Cancer Treat. Rev. 1980, 7, 95-112.
9. Duch, D. S.; Edelstein, M. P.; Bowers, S. W.; Nichol, C. A. Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW301U), a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res. 1982, 42, 3987-3994.
10. Sigel, C. W.; Macklin, A. W.; Woolley, J. L., Jr.; Johnson, N. W.; Collier, M. A.; Blum, M. R.; Clendenin, N. J.; Everitt, B. J. M.; Grebe, G.; Mackars, A.; Foss, R. G.; Duch, D. S.; Bowers, S. W.; Nichol, C. A. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. Natl. Cancer Instit. Monogr. 1897, 5, 27-35.
11. Elslager, E. F.; Johnson, J. L.; Werbel, L. M. Folate antagonists. 20. Synthesis, antitumor, and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines. J. Med. Chem. 1983, 26, 1753-1760.
12. Lin, J. T.; Bertino, J. R. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest. 1991, 9, 159-172.
13. Duch, D. S.; Edelstein, M. P.; Nichol, C. A. Inhibition of histamine-metabolising enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists. Mol. Pharmacol. 1980, 18, 100-104.
14. Klohs, W. D.; Steinkampf, R. W.; Besserer, J. A.; Fry, D. W. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U. Cancer Lett. 1986, 31, 253-260.
15. Assaraf, Y. G.; Molina, A.; Schimke, R. T. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug resistant phenotype. J. Natl. Cancer Inst. 1989, 81, 291-294.
16. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
17. Baccanari, D. P.; Tansik, R. L. Multiple drug resistance and its relationship to brain penetration by lipophilic dihydrofolate reductase inhibitors. Proc. Am. Assoc. Cancer Res. 1990, 31, 339.
18. Kuyper, L. F.; Baccanari, D. P.; Jones, M. L.; Hunter, R. N.; Tansik, R. L.; Joyner, S. S.; Boytos, C. M.; Rudolph, S. K.; Knick, V.; Wilson, H. R.; Caddell, J. M.; Friedman, H. S.; Comley, J. C. W.; Stables, J. N. High affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. J. Med. Chem. 1996, 39, 892-903.
19. Chio, L.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
20. Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
21. Voelker, R. More choices in treating AIDS-related pneumonia. J. Am. Med. Assoc. 1994, 271, 176-177.
22. Sattler, F. R.; Allegra, C. J.; Verdegem, T. D. Trimetrexate-leucovorin dosage evaluation study for the treatment of Pneumocystis carinii pneumonia. J. Infect. Dis. 1990, 161, 91-96.
23. Queener, S. F. New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J. Med. Chem. 1995, 38, 4739-4759.
24. Griffin, R. J.; Meek, M. A.; Schwalbe, C. H.; Stevens, M. F. G. Structural studies on bioactive compounds. Part 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant cell line. J. Med. Chem. 1989, 32, 2468-2474.
25. Griffin, R. J.; Stevens, M. F. G. Unpublished results.
26. Griffin, R. J.; Schwalbe, C. H.; Stevens, M. F. G.; Wong, K. P. Structural studies on bioactive compounds. Part 3. Re-examination of the hydrolysis of the antimalarial drug pyrimethamine and related derivatives and crystal structure of a hydrolysis product. J. Chem. Soc., Perkin Trans, 1 1985, 2267-2276.
27. Clemo, G. R.; Perkin, W. H.; Robinson, R. Strychnine and Brucine, Part II. J. Chem. Soc. 1924, 725, 1751-1804.
28. Lindley, J. Copper assisted nucleophilic substitution of aryl halogen. Tetrahedron 1984, 40, 1433-1456.
29. Yamamoto, H. Anomalous halogen to dimethylamino replacement with N,N-dimethylformamide catalyzed by ethylenediamine or 2-aminoethanol. Bull. Chem. Soc. Jpn. 1982, 55, 2685-2686.
30. Bliss, E. A.; Griffin, R. J.; Stevens, M. F. G. Structural studies on bioactive compounds. Part 5. Synthesis and properties of 2,4-diaminopyrimidine dihydrofolate reductase inhibitors bearing lipophilic azido groups. J. Chem. Soc., Perkin Trans, 1 1987, 2217-2228.
31. Reuman, M.; Myers, A. I. The synthetic utility of oxazolines in aromatic substitution. Tetrahedron 1985, 41, 837-860.
32. Levin, J. I.; Weinreb, S. M. A novel ring cleavage reaction of oxazolines. Tetrahedron Lett. 1982, 23, 2347-2350.
33. Vankar, Y. D.; Chaudhuri, N. C.; Rao, C. T. Regioselective reductions of 2,3-epoxyacetals with zinc-chlorotrimethylsilane and lithium aluminum-hydride. Convenient synthesis of 1,2- and 1,3-diones. Tetrahedron Lett. 1987, 28, 551-554.
34. Griffin, R. J.; Stevens, M. F. G. Structural studies on bio-active compounds. Part 21. Acid-promoted debenzylations in antitumor 2,4-diamino-5-[4-(N-alkylbenzylamino)-3-nitrophenyl)-6-ethylpyrimidines. Anti-Cancer Drug Des. 1992, 7, 443-449.
35. DeGraw, J. I.; Brown, V. H.; Tagawa, H.; Kisliuk, R. L.; Gaumont, Y.; Sirotnak, F. M. Synthesis and anti-tumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin. J. Med. Chem. 1982, 25, 1227-1230.
36. Webber, S. E.; Bleckman, T. M.; Attard, J.; Deal, J. G.; Kathardekar, V.; Welsh, K. M.; Webber, S.; Janson, C. A.; Matthews, D. A.; Smith, W. W.; Freer, S. T.; Jordan, S. R.; Bacquet, R. C.; Howland, E. F.; Booth, C. L. J.; Ward, R. W.; Hermann, S. M.; White, J.; Morse, C. A.; Hilliard, J. A.; Barlett, C. A. Design of thymidylate synthase inhibitors using protein crystal structures. The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J. Med. Chem. 1993, 36, 733-746.
37. Chio, L.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
38. Gangjee, A.; Mavandadi, F.; Queener, S. F.; McGuire, J. J. Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductase J. Med. Chem. 1995, 38, 2158-2165.
39. Jackson, R. C.; Hart, L. I.; Harrap, K. R. Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrofolate reductases. Cancer Res. 1976, 36, 1991-1997.
40. Sirotnak, F. M.; Moccio, D. M.; Goutas, L. J.; Kelleher, L. E.; Montgomery, J. A. Biochemical correlates of responsiveness and collatoral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res. 1982, 42, 924-928.
41. Rachedi, A.; Sansom, C. E.; Groom, C. R.; Thillet, J.; Griffin, R. J.; Geddes, A. J. Unpublished results.
42. Denny, B. J.; Ringan, N. S.; Schwalbe, C. H.; Lambert, P. A.; Meek, M. A.; Griffin, R. J.; Stevens, M. F. G. Structural studies on bioactive compounds. 20. Molecular modeling and crystallographic studies on methylbenzoprim, a potent inhibitor of dihydrofolate reductase. J. Med. Chem. 1992, 35, 2315-2320.
43. Richter, P.; Wagner, G. Synthesis of 3- and 4-amidinobenzaldehyde hydrochloride. Pharmazie 1978, 33, 39-41.
44. Brown, H. C.; Krishnamurthy, S. Lithium triethylborohydride. An exceptionally powerful nucleophile in displacement reactions with organic halides. J. Am. Chem. Soc. 1973, 95, 1669-1671.
45. Bertino, J. R.; Fischer, G. A. Technique for the study of resistance to folic acid antagonists. Methods Med. Res. 1964, 10, 297-299.
46. Webber, S.; Whiteley, J. M. Comparative activity of rat liver dihydrofolate reductase with 7,8-dihydrofolate and other 7,8-dihydropteridines. Arch. Biochem. Biophys. 1985, 236, 681-690.